

## GRAPPA EU Financial Statements for the year ending 31 December 2024

RSIN number 859999920

Chamber of Commerce Registration number 47408651

<u>Income and expenses for the year ending 31 December 2024</u>					
				2024	2023
				Euros	Euros
Business expenses				0	247.98
Funded by GRAPPA				0	-247.98
Expenditure related to HIPPOCRATES				8,073.20	10,106.19
Funded by HIPPOCRATES Grant monies				8,073.20	-10,106.19
Net Income				0	0
<u>Statement of cash flow for the year 2024</u>					
				Euros	
Balance at 01 January 2024				101,811.23	
HIPPOCRATES grant monies received				7,687.40	
HIPPOCRATES project expenses				8,073.20	
Balance at 31 December 2024				101,425.43	
<u>Balance Sheet</u>				at 31 Dec 2024	at 31 Dec 2023
				Euros	Euros
<u>Assets</u>					
Bank				101,425.43	101,811.23
Accounts receivable - GRAPPA				466.85	466.85
				101,892.28	102,278.08
<u>Liabilities</u>					
Commitments relating to the HIPPOCRATES study				101,892.28	102,278.08

## GRAPPA EU Activities for the year ended 31 December 2024

GRAPPA EU furthers the work of GRAPPA with a specific focus on participating in research projects relating to psoriasis and psoriatic arthritis in the European Union.

During the year 2024, GRAPPA EU continued its activities as a partner within the HIPPOCRATES project, having received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No.101007757. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

Within the HIPPOCRATES project, GRAPPA EU continues its efforts to encourage and facilitate scientific GRAPPA-EU members to provide important cohort data to the Secure HIPPOCRATES Data Management Platform. GRAPPA EU also supported the involvement of Patient Research Partners and contributed to the PPI evaluation study. Finally, GRAPPA-EU actively considers its role and contribution to the HIPPOCRATES research consortium after the official end of the project.